TITLE: Long-term 5HT3 Antagonist Use for Schizophrenia: Clinical Evidence and Guidelines

DATE: 25 June 2014

RESEARCH QUESTIONS

1. What are the clinical benefits and harms of long term (>5 day) 5HT3 antagonist use for the treatment of schizophrenia?
2. What are the evidence-based guidelines for the use of 5HT3 antagonists for the treatment of schizophrenia?

KEY MESSAGE

One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2010, Issue 6), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and June 20, 2014. Internet links were provided, where available.

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.
One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia. No relevant health technology assessments, non-randomized studies, or evidence-based guidelines were identified.

Additional references of potential interest are provided in the appendix.

**Health Technology Assessments**
No literature identified.

**Systematic Reviews and Meta-analyses**


**Randomized Controlled Trials**


**Non-Randomized Studies**
No literature identified.

**Guidelines and Recommendations**
No literature identified.

**PREPARED BY:**
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Review Articles
